Clinical trials
-
Pfizer ends Danuglipron development after liver injury in trial
Danuglipron belongs to a class of drugs targeting the GLP-1 hormone, which plays a role in appetite regulation and weight management.
-
Akagera Medicines reports promising early results for new TB antibiotic
This oxazolidinone antibiotic targets pulmonary TB, with a preclinical study assessing its safety and pharmacokinetics.
-
Novo Nordisk’s Ozempic improves walking distance in PAD patients with Type 2 diabetes
Peripheral artery disease is a serious type of atherosclerotic cardiovascular disease that is often underdiagnosed and affects about 230 million people worldwide.
-
Epicrispr raises US$68M for pioneering FSHD treatment set for 2025 trial
The therapy is designed to address the root cause of facioscapulohumeral muscular dystrophy (FSHD) by silencing the aberrant expression of the DUX4 gene, which is incorrectly activated in patients with this condition, leading to progressive muscle degeneration.
-
TaiMed’s HIV therapy shows strong Phase 2a results
The study highlighted the regimen’s effectiveness in maintaining viral suppression, with an impressive 94% of participants keeping their viral RNA levels below 50 copies/mL throughout the 24-week treatment period.
-
-
-
-
-
